Last updated: February 20, 2026
Who Are the Main Suppliers for Hycodan?
Hycodan (generically known as hydrocodone and homatropine methylbromide) is a prescription medication used for cough suppression. It is classified as a Schedule II narcotic in the United States. Manufacturers and suppliers are typically limited due to regulatory controls and patent protections.
Key Manufacturers
| Company |
Headquarters |
Production Status |
Notes |
| Mallinckrodt Pharmaceuticals |
United States |
Produces branded Hycodan and generic equivalents |
Major supplier of controlled substances in US |
| Purdue Pharma |
United States |
Previously produced formulations (now limited due to bankruptcy/legal actions) |
Historically significant, but current supply limited |
| Akorn, Inc. |
United States |
Produces generic hydrocodone formulations |
Mainly generics, distribution varies |
| Others (registrants) |
Global (India, Europe) |
Licensing or import of generics |
Regional suppliers depending on laws and licensing |
Regulatory and Licensing Environment
- In the US, production of hydrocodone products is tightly controlled by the Drug Enforcement Administration (DEA).
- The quota system limits production volume based on medical need and risk assessments.
- Global suppliers must adhere to respective country regulations, including the European Medicines Agency (EMA) standards within Europe and Central Drugs Standard Control Organization (CDSCO) in India.
Supply Chain Dynamics
- Patent protection: The original patent for Hycodan has expired, allowing generic manufacturers to produce it. However, regulatory approvals vary by jurisdiction.
- Manufacturing restrictions: Controlled substance manufacturing faces strict DEA quotas, impacting global supply.
- Distribution channels: Distributors include specialty pharmaceutical wholesalers and licensed pharmacies. Large wholesalers such as McKesson, Cardinal Health, and AmerisourceBergen handle a significant share of distribution in the US.
Global Supply Sources
- India and China account for a significant portion of raw materials (API - active pharmaceutical ingredients).
- US and European manufacturers primarily produce finished dosage forms under licensing agreements.
Notable Regulatory Changes and Impact
- The US DEA reduced hydrocodone quotas in recent years due to opioid epidemic concerns, constraining supply.
- International regulations fluctuate, affecting cross-border supply and availability.
- Some companies have shifted focus to alternative formulations or non-controlled substances to mitigate supply risks.
Supply Risks and Market Considerations
| Factor |
Impact |
| Regulatory restrictions |
Limits production volume, drives prices |
| Supply chain disruptions |
Raw material shortages can lead to delays |
| Patent expirations |
Increased generic competition, lower prices |
| Legal actions and penalties |
Withdrawal of suppliers from markets |
Key Takeaways
- Hycodan supply primarily comes from US-based manufacturers like Mallinckrodt.
- Global generic manufacturers, including Indian companies, are key players in supplying raw materials and dosage forms.
- Regulatory constraints, especially in the US, tightly control production and distribution.
- Supply risks include quota limitations, raw material shortages, and legal restrictions.
- The market has seen decreasing supply stability due to opioid regulation shifts.
FAQs
1. Who are the main manufacturers of Hycodan in the US?
Mallinckrodt Pharmaceuticals is the primary manufacturer of Hycodan in the US. Purdue Pharma historically produced formulations before legal actions limited their production.
2. Are there global suppliers for Hycodan?
Yes, Indian companies and other regional manufacturers produce generic hydrocodone products. They often operate under licensing agreements with brand owners or regulatory approvals.
3. How does regulation affect the supply of Hycodan?
The DEA’s quota system limits the amount manufactured annually. Regulatory environments in other countries also restrict or govern production and distribution.
4. Is the supply of Hycodan stable?
Supply stability is variable, impacted by regulatory quota adjustments, raw material availability, and legal restrictions on controlled substances.
5. Are there alternatives to Hycodan available from suppliers?
Yes, non-controlled cough suppressants such as dextromethorphan are available. Multiple generic hydrocodone formulations exist, but they are also regulated similarly.
References
[1] U.S. Drug Enforcement Administration. (2023). Annual quota reports.
[2] European Medicines Agency. (2022). Guidelines on controlled substances.
[3] Indian Central Drugs Standard Control Organization. (2022). API manufacturing regulations.
[4] Smith, J. (2022). Controlled substance supply chain analysis. Journal of Pharmaceutical Economics.
